ADRB2 cancer markers

• US 8,900,819 B2
• Filed: 11/01/2011
• Issued: 12/02/2014
• Est. Priority Date: 01/19/2007
• Status: Active Grant

• Current Assignee: Board of Regents of the University of Michigan (University of Michigan)
• Original Assignee: Board of Regents of the University of Michigan (University of Michigan)
• Inventors: Chinnaiyan, Arul M., Yu, Jindan, Mehra, Rohit
• Primary Examiner(s): Strzelecka, Teresa E
• Application Number:
  US13/286,820
• Publication Number:
  US 20120046196A1
• Time in Patent Office: 1,127 Days
• Field of Search: None
• US Class Current: 435/7.1
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ADRB2 markers for cancer.

Claims

1. A method for identifying risk of prostate cancer recurrence in a prostate cancer patient, comprising:

a) detecting the level of expression of Adrenergic Receptor, Beta 2 (ADRB2) polypeptide compared to normal expression of ADRB2 polypeptide in a prostate cancer biopsy sample from a patient diagnosed with prostate cancer by detecting the binding of an antibody that specifically binds to an ADRB2 polypeptide using an immunoassay;

b) comparing the level of expression of ADRB2 polypeptide in said sample to the level in a sample of normal prostate tissue; and

c) identifying said patient as being at risk of recurrence of prostate cancer when said expression level is decreased relative to the level in normal prostate tissue.

2. The method of claim 1, wherein said recurrence of disease after prostatectomy comprises development of metastatic cancer.